FDA approves Teva’s Austedo for tardive dyskinesia
Teva’s Austedo is now the first and only therapy approved in the US to treat both tardive dyskinesia and chorea associated with Huntington’s disease.
Read More
Tag: tardive dyskinesia
US clears first drug for tardive dyskinesia
Neurocrine Biosciences’ Ingrezza has become the first drug approved to treat the hyperkinetic movement disorder tardive dyskinesia in the US.
Read More
- PMGroup Worldwide Ltd welcomes MAD World Summit
- Argenx receives review from FDA for VYVGART in seronegative gMG
- Nuclera extends Series C funding to advance antibody engineering
- Cellistic launches new iPSC-based platforms to expand immuno-oncology therapies
- Fabentech secures French approval for Ricimed antidote
